Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Anyong Biotechnology's Locally Sourced 'Santé Silver Perch Essence' Fulfilling Increasing Demand in The APAC Wellness Industry

KAOHSIUNG, Taiwan, Sept. 19, 2022 /PRNewswire/ -- Taiwan-based Anyong Biotechnology, has created a locally-sourced Santé Silver Perch Essence out of ecologically farmed, certified, and traceable silver perch in major markets such asTaiwan, the United States, Singapore, and Malaysia. As consumers'...

2022-09-19 16:30 1750

MagicTouch SCB receives IDE approval for In-Stent Restenosis indication

TAMPA, Fla., Sept. 19, 2022 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval forMagicTouch Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR).

2022-09-19 12:20 1861

MagicTouch SCB receives IDE approval for In-Stent Restenosis indication

Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth

SHANGHAI, Sept. 19, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific ...

2022-09-19 08:00 4038

CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®

SINGAPORE, Sept. 17, 2022 /PRNewswire/ -- CellResearch Corporation, a Singapore -based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at theUnivers...

2022-09-17 00:20 2349

New treatment for rare cancer cholangiocarcinoma approved in Australia

* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement * PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct c...

2022-09-15 21:00 1377

Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance

SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for...

2022-09-15 17:07 1222

Austar Lifesciences Announces 2022 Interim Results

Benefiting from the Growth in the Business Segment of Liquid and Bioprocess System and the Increased Capability of Comprehensive Integrated Solutions,its Businesses Grew Steadily Revenue Increased by 29.1% to RMB 1,104 million Operation Highlights (RMB'000) For the six months ended 30 June ...

2022-09-15 16:53 3447

Winmate Stainless Panel PCs and Displays Solution for Food Packaging Automation

Increasing efficiencies in food processing with Winmate's hygienic and easy to clean solutions TAIPEI, Sept. 15, 2022 /PRNewswire/ -- The urgency of the global low-carbon circular economy impacted the food and drinks industry. Pushing the manufacturer to innovate while increasing their productiv...

2022-09-15 16:21 1468

SIFI TO PRESENT NEW SCIENTIFIC DATA AND LAUNCH A NEW INTRAOCULAR LENS DURING THE 40TH CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS

CATANIA, Italy, Sept. 15, 2022 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announces 3 scientific presentations on its latest innovations during the upcoming Congress of The European Society of Cataract and Refractive Surgeons (ESCRS) which will take place from 16th to 20th ...

2022-09-15 15:00 1513

J INTS BIO, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022)

SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' at the 2022 edition of the European Society for Medical Oncology Congress (ESMO 2022) held inParis, France from 9th to 13th September...

2022-09-15 14:12 1019

J INTS BIO, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022)

Juniper Biologics Establishes Global Headquarters in Singapore

Juniper Biologics' investment will support the growth and innovation of Singapore's pharmaceutical sector SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its ...

2022-09-15 09:53 1703

Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

SUZHOU, China, Sept. 14, 2022 /PRNewswire/ --Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST003, its fir...

2022-09-14 14:18 2128

Nippon Express Obtains GDP Certification of Compliance with WHO Standards at East Japan Pharmaceutical Center

- Dedicated Pharmaceutical Logistics Facility Offers Storage and Transport in Two Temperature Ranges - TOKYO, Sept. 14, 2022 /PRNewswire/ -- Nippon Express Co., Ltd. (hereafter "Nippon Express"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired Good Distribution Practice (GDP) cert...

2022-09-14 14:00 1719

Fosun: Foreign Media Reports about "Regulatory Authorities Asking Banks to Examine their Exposure to Fosun" are Completely False

HONG KONG, Sept. 14, 2022 /PRNewswire/ -- In response to foreign media reports about "Chinese regulatory authorities asking banks and some of the state-owned companies to examine their exposure to Fosun" on 13 September, Fosun said such reports are completely false. It is understood that Fosun h...

2022-09-14 12:11 2576

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveileda new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help An...

2022-09-14 08:30 3281

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence

Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future LAUSANNE, Switzerland, Sept. 14, 2022 /PRNewswire/ -- Debiopharm Innovation Fund, the strategic investm...

2022-09-14 00:48 1420

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

BIRMINGHAM, England, Sept. 13, 2022 /PRNewswire/ -- Concept Medical announces the successful completion of the TRANSFORM 1 RCT (TReAtmeNt of Small coronary vessels: Randomized controlled trialFOR MagicTouch S...

2022-09-13 22:15 1763

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101

An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lung Cancer TAIPEI, Sept. 13, 2022 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients, announ...

2022-09-13 22:00 1846

Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics

The proprietary platform is versatile, equally effective with different cargoes, routes of administration MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today ann...

2022-09-13 20:38 1559

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (...

2022-09-13 20:00 2060

1 ... 111 112 113114115 116 117 ... 294